Rule 38.5_A - Avadel Pharmaceuticals plc
14th Nov 2025 09:20
FORM 38.5(a) (EPT/RI)
IRISH TAKEOVER PANEL
DEALING DISCLOSURE UNDER RULE 38.5(a) OF THE IRISHTAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022BY A CONNECTED EXEMPT PRINCIPAL TRADER WITHRECOGNISED INTERMEDIARY STATUS AND DEALING INA CLIENT-SERVING CAPACITY
1. KEY INFORMATION
(a) Name of exempt principal trader: | Morgan Stanley Capital Services LLC |
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree | Avadel Pharmaceuticals plc |
(c) Name of the party to the offer with which exempt principal trader is connected: (Note 1) | Avadel Pharmaceuticals plc |
(d) Date dealing undertaken: | 13 November 2025 |
(e) In addition to the company in 1(b) above, is the exempt principal trader also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" | N/A |
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER (Note 2)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security (Note 3) | Purchases/ sales | Totalnumber of securities | Highest price per unit paid/ received | Lowest price per unit paid/ received |
0.01 ordinary shares | PURCHASES | 3,935 | 19.2400 USD | 19.0600 USD |
0.01 ordinary shares | SALES | 23 | 19.2400 USD | 19.2400 USD |
(b) Cash-settled derivative transactions
Class of relevant security | Product description e.g. CFD | Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position | Number of reference securities (Note 4) | Price perunit (Note 5) |
0.01 ordinary shares | CFD | increasing a short position | 60 | 19.1701 USD |
0.01 ordinary shares | CFD | increasing a short position | 11 | 19.1868 USD |
0.01 ordinary shares | CFD | increasing a short position | 1 | 19.1931 USD |
0.01 ordinary shares | CFD | increasing a short position | 21 | 19.1998 USD |
0.01 ordinary shares | CFD | increasing a short position | 17 | 19.2049 USD |
0.01 ordinary shares | CFD | reducing a long position | 3,800 | 19.2100 USD |
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of relevant security | Product description e.g. call option | Writing, purchasing, selling, varying etc. | Number of securities to which option relates (Note 4) | Exercise price per unit | Type e.g. American, European etc. | Expirydate | Option money paid/ received per unit |
N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
(ii) Exercise
Class of relevant security | Product description e.g. call option | Exercising/ exercised against | Number of securities | Exercise priceper unit (Note 5) |
N/A | N/A | N/A | N/A | N/A |
(d) Other dealings (including transactions in respect of new securities)
Class of relevant security | Nature of dealing e.g. subscription, conversion, exercise | Details | Price per unit (if applicable) (Note 5) |
N/A | N/A | N/A | N/A |
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" |
NONE |
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
NONE |
Date of disclosure: | 14 November 2025 |
Contact name: | Claire Gordon |
Telephone number: | +44 141 245-8893 |
Public disclosures under Rule 38 of the Rules must be made to a Regulatory Information Service.